Pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, ANG Lifesciences India has informed that the Company has received the In-principal Approval vide letter no. LO/Migration/SC/IP/258/2021-22 dated 01-Nov.-2021 for Migration of equity shares of the company from BSE SME Platform to Main Board of BSE. The company enclosed the copy of In principal Approval of the BSE.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1867.80 |
| Dr. Reddys Lab | 1301.30 |
| Cipla | 1433.10 |
| Zydus Lifesciences | 1112.10 |
| Lupin | 2356.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: